Earnest Partners LLC Sells 1,204 Shares of Relx Plc (NYSE:RELX)

Earnest Partners LLC trimmed its stake in Relx Plc (NYSE:RELX) by 1.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 69,655 shares of the technology company’s stock after selling 1,204 shares during the quarter. Earnest Partners LLC’s holdings in Relx were worth $3,164,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP boosted its stake in Relx by 4.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,189,886 shares of the technology company’s stock valued at $144,885,000 after acquiring an additional 121,831 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in Relx by 50.3% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,968,739 shares of the technology company’s stock valued at $89,420,000 after acquiring an additional 658,655 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in Relx by 2.6% in the fourth quarter. Envestnet Asset Management Inc. now owns 1,898,927 shares of the technology company’s stock valued at $86,249,000 after acquiring an additional 48,336 shares during the last quarter. Natixis Advisors LLC boosted its stake in Relx by 2.8% in the fourth quarter. Natixis Advisors LLC now owns 1,202,592 shares of the technology company’s stock valued at $54,622,000 after acquiring an additional 32,739 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Relx in the fourth quarter valued at about $44,516,000. 15.02% of the stock is currently owned by hedge funds and other institutional investors.

Relx Stock Performance

Relx stock opened at $53.37 on Tuesday. The firm’s 50 day simple moving average is $49.59 and its 200 day simple moving average is $48.29. The company has a current ratio of 0.52, a quick ratio of 0.47 and a debt-to-equity ratio of 1.46. The firm has a market capitalization of $98.78 billion, a PE ratio of 28.69, a price-to-earnings-growth ratio of 2.73 and a beta of 0.84. Relx Plc has a 1-year low of $40.77 and a 1-year high of $53.56.

Relx Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Wednesday, June 25th. Investors of record on Friday, May 9th will be issued a dividend of $0.5586 per share. This represents a yield of 1.6%. The ex-dividend date of this dividend is Friday, May 9th. This is a positive change from Relx’s previous semi-annual dividend of $0.23. Relx’s dividend payout ratio is 59.68%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on RELX. StockNews.com cut shares of Relx from a “buy” rating to a “hold” rating in a research note on Tuesday, March 4th. Morgan Stanley restated an “overweight” rating on shares of Relx in a research note on Wednesday, April 16th. Redburn Atlantic began coverage on shares of Relx in a research note on Wednesday, January 8th. They set a “buy” rating on the stock. The Goldman Sachs Group began coverage on shares of Relx in a research note on Wednesday, March 26th. They set a “buy” rating on the stock. Finally, Barclays upgraded shares of Relx from an “equal weight” rating to an “overweight” rating in a research note on Friday, March 14th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy”.

Relx Profile

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.